Tirzepatide noninferior to dulaglutide with respect to composite of death from cardiovascular causes, myocardial infarction, or stroke.
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio NEW ORLEANS — Young people with type 2 ...
Another glucagon-like peptide-1 (GLP1) agonist, dulaglutide (Trulicity, Lilly), is poised to be a new option for glycemic control in youth ages 10 to 18 with type 2 diabetes, given as a weekly ...
Dulaglutide reduces liver fat content in patients with type 2 diabetes (T2D) and nonalcoholic fatty liver disease, when used in combination with standard T2D treatment. Although previous data show ...
TORONTO, June 19, 2020 (GLOBE NEWSWIRE) -- New real-world data showed Trulicity ® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of semaglutide ...
- Trulicity, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the only non-insulin, injectable diabetes treatment available in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 25, 2014 ...
Trulicity is a prescription drug prescribed to lower blood glucose levels and treat type diabetes. Although it is FDA approved for treating diabetes it is not approved for weight loss. Despite this ...
Results from a phase 3 study of patients with type 2 diabetes uncontrolled with metformin indicate that adding injections of the investigational glucagonlike peptide 1 (GLP-1)–receptor agonist ...
Adults with type 2 diabetes and mild to moderate chronic kidney disease assigned the once-weekly GLP-1 receptor agonist dulaglutide experienced a similar reduction in HbA1c vs. those assigned insulin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback